Gustavo Alva, MD
Psychiatry · Orange, CANPI 1417030222
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,013,645 of the $5,769,736 with a category attached, or 69.6%. It is spread thinly across 53 manufacturers, the largest accounting for just 18.4%. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 6,671 payments — averaging $864.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1.1M
- AbbVie$703K
- Otsuka America Pharmaceutical, Inc.$509K
- Johnson & Johnson$473K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$435K
- Axsome Therapeutics, Inc.$370K
- plus $2.2M from 47 others
Across 1,241 payments — averaging $3277.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$669K
- Livanova USA, Inc.$669K
- AbbVie$518K
- Boehringer Ingelheim$473K
- Acadia Pharmaceuticals Inc$261K
- Eisai Inc.$260K
- plus $1.2M from 17 others
What the payments were for
- Consulting fees$814,00014%
- Speaking & faculty fees$4,013,64570%
- Travel & lodging$691,63312%
- Food & beverage$156,9563%
- Education$2990%
- Other$93,2042%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$840,157
- VRAYLAR$687,341
- LYBALVI$543,576
- AUSTEDO$526,402
- INVEGA SUSTENNA$431,448
- CAPLYTA$428,247
- INVEGA TRINZA$415,053
- REXULTI$395,866
- INGREZZA$350,248
- Auvelity$346,011
- Austedo XR$277,206
- NUPLAZID$262,581
- Fanapt$258,899
- ABILIFY MAINTENA$257,638
- UZEDY$229,803
- ARISTADA INITIO$198,191
- COBENFY$159,662
- NUEDEXTA$129,706
- NEUROSTAR TMS THERAPY SYSTEM$93,338
- ABILIFY ASIMTUFII$77,952
How this compares
$5,769,736 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 28 | $312,974 |
| NuplazidPimavanserin Tartrate | 29 | $138,032 |
| VraylarCariprazine Hcl | 57 | $101,709 |
| IngrezzaValbenazine Tosylate | 11 | $93,165 |
| UzedyRisperidone | 20 | $85,212 |
| TrintellixVortioxetine Hydrobromide | 128 | $74,833 |
| NuedextaDextromethorphan Hbr/Quinidine | 34 | $54,410 |
| RexultiBrexpiprazole | 32 | $49,671 |
| AuvelityDextromethorphan Hbr/Bupropion | 37 | $44,911 |
| Abilify MaintenaAripiprazole | 11 | $28,690 |
| CaplytaLumateperone Tosylate | 13 | $21,271 |
| BelsomraSuvorexant | 40 | $19,839 |
| NamzaricMemantine Hcl/Donepezil Hcl | 25 | $16,427 |
| OzempicSemaglutide | 12 | $10,812 |
| QuviviqDaridorexant Hcl | 23 | $10,688 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $1,064,391 | $398,18648 claims |
| Acadia Pharmaceuticals IncNuplazid | $281,288 | $138,03229 claims |
| AbbVieVraylar, Namzaric | $703,332 | $118,13682 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $361,694 | $93,16511 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $508,956 | $78,36143 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $14,200 | $74,833128 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $102,524 | $54,41034 claims |
| Axsome Therapeutics, Inc.Auvelity | $370,237 | $44,91137 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $435,314 | $21,27113 claims |
| MerckBelsomra | $262 | $19,83940 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $11,146 | $10,68823 claims |
| Eisai Inc.Dayvigo | $39,824 | $8,87328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Orange
- Rimal BeraOrange$138K
- Steven PotkinOrange$108K
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.